FDA Interim Policy (2025)

The U.S. Food and Drug Administration (FDA) is implementing significant changes to its interim policy regarding drug compounding, particularly affecting peptides. Effective January 7, 2025, new rules will tighten the criteria for bulk substances eligible for compounding exemptions, while the resolution of drug shortages, such as for semaglutide, is narrowing the pathway for compounded copies. These shifts underscore the FDA's commitment to regulating compounded drugs and ensuring patient safety.

Stricter Compounding Rules for Bulk Substances

The FDA's interim policy guidance, effective January 7, 2025, introduces a materially tightened posture for newly nominated bulk substances. Under this revised policy, substances nominated on or after this date will no longer fall under the older, more lenient interim categorization. Critically, a substance must now meet specific criteria to be eligible for 503A compounding exemptions: it must be monograph-backed, a component of an FDA-approved drug, or already on the 503A bulks list. This change significantly restricts the ability of compounding pharmacies (503A) to use novel or unapproved bulk substances, impacting pipeline decisions for peptide therapeutics.

Biologics and Compounding Exemptions

A key clarification from the FDA is that biologics are explicitly not eligible for either 503A or 503B compounding exemptions. This distinction is crucial for understanding the regulatory landscape of complex biological products, which undergo a more rigorous approval process due to their inherent complexity and potential immunogenicity. This policy ensures that biologics are subject to the full FDA approval pathway, preventing their circumvention through compounding exemptions.

Resolution of Semaglutide Shortage and Policy Impact

The resolution of the semaglutide and tirzepatide shortages has had a direct and significant impact on compounding policy. The FDA had previously allowed compounding of these drugs under a "shortage" pathway. However, with the resolution of these shortages, this pathway has materially narrowed. The FDA's wind-down for 503A compounding of semaglutide concluded on April 22, 2025. Once a drug shortage is resolved, the product is generally considered commercially available again, removing the justification for widespread compounding. The FDA has also issued multiple communications regarding concerns with compounded semaglutide and tirzepatide, including dosing errors, adverse events, and misleading promotion, reinforcing its stance against unapproved compounded versions, especially when approved alternatives are available.

FDA Scrutiny on GLP-1 Receptor Agonists

The FDA has demonstrated active scrutiny around compounded copies of GLP-1 receptor agonists, such as semaglutide and liraglutide, which are widely used for type 2 diabetes, obesity, and cardiovascular risk reduction. These drugs, like semaglutide, have seen huge demand, leading to a proliferation of compounded versions and "gray-market" sales. The agency has taken action against mass-marketed non-FDA-approved GLP-1 compounded products and consistently warned that compounded drugs are not FDA-approved. This vigilance highlights the FDA's concern over patient safety and the integrity of the drug supply chain, particularly for high-demand medications.

Outlook

The FDA's interim policy, particularly the changes effective January 2025, signals a more stringent regulatory environment for drug compounding. The tightening of bulk substance eligibility and the narrowing of compounding pathways following resolved drug shortages emphasize the FDA's commitment to ensuring that compounded drugs meet necessary safety and quality standards. For peptide therapeutics, this means a greater reliance on legal sourcing and a clear distinction between FDA-approved products and compounded alternatives, especially in areas of high demand and active regulatory oversight.